| Document |
Document Title |
|
WO/2021/070150A1 |
The present invention relates to an inhalable composition comprising a therapeutically effective dosage amount of compound (I), 2-{4-[(2S)-1,1-difluoro-2-hydroxypropyl]phenyl}-N-{4-[3-(2-e
thylphenyl) pyrazine-2-yl]phenyl}acetamide or a ...
|
|
WO/2021/068950A1 |
Disclosed in the present invention are an amide compound and the medical use thereof as a STING inhibitor. Specifically, disclosed is a compound represented by formula I or formula II, or a pharmaceutically acceptable salt or ester or so...
|
|
WO/2021/064561A1 |
An improved process for the preparation of Elagolix Sodium having the structural formula (I). The present invention relates to highly pure compound of formula (VI) as a solid which is useful in the preparation of Elagolix sodium. The pre...
|
|
WO/2021/063856A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2021/063821A1 |
The present invention covers pyrimidinedione derivatives of general formula (I) : (I), in which R1, R2, R4, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, ...
|
|
WO/2021/063207A1 |
Provided are a compound as shown in formula (I), which formula is as follows, and racemates, stereoisomers, tautomers, isotopic markers, solvates, polymorphs and oxynitrides of the compound, or a pharmaceutically acceptable salt thereof,...
|
|
WO/2021/062559A1 |
This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are poten...
|
|
WO/2021/059017A1 |
Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine...
|
|
WO/2021/061695A1 |
Methods of treating EGFR mutant-related cancers with a combination of an EGFR inhibitor of Formula (I) and the CDK4/6 inhibitor of Formula (II) and use of combinations of these compounds in the manufacture of medicaments for the treatmen...
|
|
WO/2021/057009A1 |
The present invention provides an improved N-heterocyclic planar optical coupling output material. The general structural formula of the N-heterocyclic planar optical coupling output material is R1-R2-R1. The structural formula of the sy...
|
|
WO/2021/059287A1 |
A method of oxygenating a benzylic C-H bond is provided. The method comprises light induced activation of an initiator and subsequent reaction with oxygen, resulting in the formation of free radicals. Subsequently, free radicals catalyze...
|
|
WO/2021/057550A1 |
The present invention provides an organic compound and an electronic device containing the organic compound, which belongs to the technical field of organic materials. The structure of the organic compound is as shown in chemical formula...
|
|
WO/2021/057264A1 |
The present disclosure relates to the technical field of organic materials, and provides a compound as represented by formula (I), a photoelectric conversion device, and an electronic device. The compound can reduce the working voltage o...
|
|
WO/2021/057975A1 |
A compound (as shown in formula I) as a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor, and a preparation method and a pharmaceutical composition thereof. Also disclosed is a use of the compound or pharmaceutical composition thereof ...
|
|
WO/2021/056922A1 |
The invention belongs to the technical field of pesticides and specifically relates to an aryl sulfide containing a benzylamine structure, a synthesis method therefor, and an application thereof. The aryl sulfide is denoted as compound I...
|
|
WO/2021/059160A1 |
The present invention provides a process for preparing a compound having the formula (I): wherein R is alkyl or alkylaryl; each of X1, X2, X3, X4 and X5 is, independently, H, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, alkylt...
|
|
WO/2021/053403A1 |
The invention provides a compound of formula (I) and processes for the manufacture of such compounds, related intermediates, compositions comprising such compounds and the use of such compounds as cytidine triphosphate synthase 1 inhibit...
|
|
WO/2021/055905A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein Q, Y, R1a, R1b, Z, W, R2, R3, R4, m, R5a and R5b are as defined in the disclosure. Also disclosed are compositions cont...
|
|
WO/2021/055849A1 |
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...
|
|
WO/2021/053495A1 |
Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target...
|
|
WO/2021/032004A9 |
Disclosed in the present invention are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present invention also provides a method for preparing said compound, a composition containing said ...
|
|
WO/2021/054896A1 |
The present invention provides improved processes for the preparation of elagolix and intermediates thereof. The intermediate of formula VII is achieved by a coupling reaction of a compound of formula V and a N-benzylidene protected comp...
|
|
WO/2021/053402A2 |
The invention provides a compound of formula (I) and related aspects.
|
|
WO/2021/054804A1 |
The present invention pertains to a pharmaceutical or food composition for preventing or treating proteopathies, the pharmaceutical or food composition containing a novel p62 ligand compound represented by chemical formula 1, or a stereo...
|
|
WO/2021/050913A1 |
The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
|
|
WO/2021/049843A1 |
The present specification relates to a compound of chemical formula 1 and an organic light emitting device comprising same.
|
|
WO/2021/044230A1 |
The present invention relates to a process for the preparation of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(tri
fluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-l
(2H)-pyrimidinyl]-l-phenylethy...
|
|
WO/2020/061375A8 |
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram -negative bacteria. Furthermore, the subject compounds and compositions are...
|
|
WO/2021/038540A1 |
The present invention relates to novel cycloalkylidene carboxylic acids and derivatives thereof useful as Bruton tyrosine kinase (BTK) inhibitors. The present disclosure also relates to processes for their preparation, pharmaceutical com...
|
|
WO/2021/041852A1 |
The disclosure provides a method for preventing or treating a flavivirus infection, a filovirus infection, a SARS-CoV-1 infection, a SARS-CoV-2 infection, or a MERS-CoV infection, the method comprising administering to a subject in need ...
|
|
WO/2021/037868A1 |
The present invention provides novel compounds having the general formula: wherein R1 to R6 and A are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2021/042022A1 |
The present disclosure provides novel compounds, compositions, and methods for modulating one or more septin proteins, e.g., septin-2. Such compounds and compositions are useful for the treatment of a cancer, e.g., endometrial, pancreati...
|
|
WO/2021/039968A1 |
The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) [wherein X1 represents CR1 or N, X2 represents CR2 or N, X3 represents CR3 or N, Y represents an optionally ...
|
|
WO/2021/035257A1 |
The invention provides compounds having STimulator of INterferon Genes (STING) agonistic bioactivity that can be used in the treatment of tumors in patients afflicted therewith. The compounds are of formula (IA), formula (I), and formula...
|
|
WO/2021/032687A1 |
A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, and analogues thereof, substituted in the 6-position by an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety, being potent inhibitors of the growth and propa...
|
|
WO/2021/032004A1 |
Disclosed in the present invention are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present invention also provides a method for preparing said compound, a composition containing said ...
|
|
WO/2021/030542A1 |
The present disclosure provides a topical pharmaceutical formulation comprising uracil and a penetration enhancer, method of administration the same. Also provided is a method of treating or preventing dermatoses associated with the admi...
|
|
WO/2021/029158A1 |
The purpose of the present invention is to provide: a sulfonamide compound which has a high decomposition rate in response to near-ultraviolet rays and which generates a superacid bis-sulfonamide, and which is highly soluble in a resist ...
|
|
WO/2021/029450A1 |
The present invention relates to: a pyrimidine sulfonamide derivative disubstituted at a specific position with a trifluoroethoxy group; and a pharmaceutical composition which is for preventing or treating cancer and comprises same as an...
|
|
WO/2021/028316A1 |
The present invention relates to compounds of Formula (I), wherein A, R1, R2 n and p are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of ...
|
|
WO/2021/026672A1 |
Provided are compounds of Formula (I) and pharmaceutical acceptable salts thereof, which are inhibitors of WDR5. Also providing pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additio...
|
|
WO/2021/027647A1 |
A bridged heterocyclyl-substituted pyrimidine compound, a preparation method therefor, and pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method fo...
|
|
WO/2021/027502A1 |
Methods of treating malaria comprising administration of compounds of Formula (I') or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the com...
|
|
WO/2021/026884A1 |
Methods for treating malaria comprises administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the comp...
|
|
WO/2021/030623A1 |
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/025976A1 |
The present disclosure includes novel substituted cyclopropyl-2,2'-bipyrimidinyl compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infec...
|
|
WO/2021/022788A1 |
Disclosed is a method for refining 5-fluorouracil, comprising the following steps: dissolving 5-fluorouracil in an organic solvent, preferably DMSO, heating and stirring until dissolved; naturally cooling the filtrate until a crystal is ...
|
|
WO/2021/025975A1 |
The present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type 2 diabetes mellitus.
|
|
WO/2021/026179A1 |
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...
|
